Impax Labs (IPXL) Promotes VP Bryan Reasons to CFO
Tweet
Share
E-mailGet Alerts IPXL Hot Sheet
Join SI Premium – FREE
Impax Laboratories, Inc. (Nasdaq: IPXL) announced today that Bryan M. Reasons has been appointed senior vice president and chief financial officer (CFO). Mr. Reasons, 45, joined Impax Laboratories in January 2012 as vice president, Finance, and has served as acting CFO since June 2012.
Prior to joining Impax Laboratories, Mr. Reasons served as vice president, Finance, and as vice president, Risk Management and General Auditor, at Cephalon, Inc. (Cephalon), a biopharmaceutical company. Following the acquisition of Cephalon by Teva Pharmaceutical Industries Ltd. (Teva), he served briefly as the vice president, Finance, of Teva. Prior to joining Cephalon in 2005, Mr. Reasons held various finance management positions at Dupont and began his career at PricewaterhouseCoopers LLP, where he held positions of increasing responsibility. He earned a bachelor’s degree in accounting from the Pennsylvania State University and an M.B.A. from Widener University and is a certified public accountant.
Prior to joining Impax Laboratories, Mr. Reasons served as vice president, Finance, and as vice president, Risk Management and General Auditor, at Cephalon, Inc. (Cephalon), a biopharmaceutical company. Following the acquisition of Cephalon by Teva Pharmaceutical Industries Ltd. (Teva), he served briefly as the vice president, Finance, of Teva. Prior to joining Cephalon in 2005, Mr. Reasons held various finance management positions at Dupont and began his career at PricewaterhouseCoopers LLP, where he held positions of increasing responsibility. He earned a bachelor’s degree in accounting from the Pennsylvania State University and an M.B.A. from Widener University and is a certified public accountant.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Charlie's Holdings names Henry Sicignano CEO amid leadership shift
- Universal Corporation's ingredients unit head to retire amid search for successor
- Emerson names Rudy Sengupta as chief technology and AI officer
Create E-mail Alert Related Categories
Management ChangesRelated Entities
Teva Pharmaceutical/CephalonSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
